Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes-Reference-Cited by-同舟云学术

Cellularity, characteristics of hematopoietic parameters and prognosis in myelodysplastic syndromes

Published:2015-05-15 Issue:3 Volume:95 Page:181-189
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Schemenau Jennifer¹,Baldus Stephan²,Anlauf Martin²,Reinecke Petra²,Braunstein Stefan²,Blum Sabine³,Nachtkamp Kathrin¹,Neukirchen Judith¹,Strup Corinna¹,Aul Carlo⁴,Haas Rainer¹,Gattermann Norbert¹,Germing Ulrich¹

Affiliation:

1. Department of Hematology, Oncology, and Clinical Immunology; University Hospital Düsseldorf; Düsseldorf Germany

2. Department of Pathology; University Hospital Düsseldorf; Düsseldorf Germany

3. Department of Hematology and Oncology; University of Lausanne; Lausanne Switzerland

4. St Johannes Hospital, Hematology, Oncology, and Clinical Immunology; Duisburg Germany

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.12512/fullpdf

Reference21 articles.

1. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes;Stadler;Leukemia,2004

2. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow;Jonásova;Br J Haematol,1998

3. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions;Sloand;J Clin Oncol,2010

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of cytomorphology and histomorphology in myelodysplastic syndromes;Frontiers in Oncology;2024-04-11

2. The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification;Leukemia;2024-01-23

3. Impact of donor marrow cellularity on outcome of allogeneic stem cell transplantation;Transplantation Reports;2023-12

4. CSF3R-mutant chronic myelomonocytic leukemia is a distinct clinically subset with abysmal prognosis: a case report and systematic review of the literature;Leukemia & Lymphoma;2023-07-03

5. MarrowQuant 2.0: A Digital Pathology Workflow Assisting Bone Marrow Evaluation in Experimental and Clinical Hematology;Modern Pathology;2023-04